Top Markets
#1 Akedo Akedo +55.65%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +47.96%
#4 Velvet Velvet +38.39%
#5 Black Phoenix Black Phoenix +34.09%
#6 Cross Cross +24.27%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.20%
#8 QANplatform QANplatform +14.54%
#9 Perle Perle +13.89%
#10 Bitway Bitway +13.56%
Coin of the day
Akedo Akedo
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Ovoca Bio plc Ovoca Bio plc

Ovoca Bio plc

OVXA
Rang in aandelen #38531
Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc... Headquartered in Dublin, Ireland, and established in 1985, Ovoca Bio plc operates as a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market innovative therapies for various female sexual dysfunctions. Its primary drug candidate, BP-101, is being developed as a medical treatment for premenopausal women diagnosed with hypoactive sexual desire disorder. This compound is presently in Phase II clinical investigation in Australia and New Zealand, and has progressed to Phase III clinical trials within Russia. Beyond its core pharmaceutical work, the company also participates in mineral exploration and offers supplementary support services. The organization, originally incorporated as Ovoca Gold plc, rebranded to Ovoca Bio plc in July 2018.
Aandeelprijs
$0.01142111
Laatst gesynchroniseerd: 2025-03-21
Marktkapitalisatie
$930.66K
Verandering (1 dag)
0.18%
Verandering (1 jaar)
0.00%
Land
IE
Handel Ovoca Bio plc (OVXA)

Categorie

Healthcare
Winst voor Ovoca Bio plc (OVXA)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Ovoca Bio plc bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Ovoca Bio plc van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE